New Anti-Chemokine Oral Drug XC8 in the Treatment of Asthma Patients with Poor Response to Corticosteroids: Results of a Phase 2A Randomized Controlled Clinical Trial

INTRODUCTION: A significant number of patients with moderate asthma remain symptomatic despite treatment with inhaled corticosteroids (ICS). These patients do not yet meet the criteria for oral corticosteroids (OCS) and monoclonal antibodies. The new anti-chemokine oral drug XC8 could represent an a...

Descripción completa

Detalles Bibliográficos
Autores principales: Romanova, Julia, Chikina, Elena, Rydlovskaya, Anastasia, Pohl, Wolfgang, Renner, Andreas, Zeifman, Alexey, Chuchalin, Alexander, Nebolsin, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671956/
https://www.ncbi.nlm.nih.gov/pubmed/33095411
http://dx.doi.org/10.1007/s41030-020-00134-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671956/
https://www.ncbi.nlm.nih.gov/pubmed/33095411
http://dx.doi.org/10.1007/s41030-020-00134-5

Ejemplares similares